Values for the percentage change in the SRX population across the thick filament for the MYBPC3-c.772G<A mutation and a mutation negative control in human cardiac myofibrils, as plotted in Fig. 4
| . | % SRX . | |||
|---|---|---|---|---|
| P . | C . | D . | All zones . | |
| Mut neg control [95% CI] | 48 [52, 43.5] | 63.4 [80.3, 55.3] | 36.2 [43.2, 29.1] | 51.3 [54.7, 47.8] |
| n | 285 | 341 | 535 | 1,161 |
| MYBPC3-c.772G<A [95% CI] | 40.8 [53.5, 31.1] | 44.3 [50, 39.5] | 52.2 [58.5, 47.8] | 44.2 [50, 37.8] |
| n | 404 | 591 | 818 | 1,813 |
| Absolute Δ SRX (%) [95% CI] | −7.2 [6.4, −18.2] | −19.2 [-9, −38.4] | 16 [24.7, 7.2] | −7.1 [-0.3, −14.7] |
| . | % SRX . | |||
|---|---|---|---|---|
| P . | C . | D . | All zones . | |
| Mut neg control [95% CI] | 48 [52, 43.5] | 63.4 [80.3, 55.3] | 36.2 [43.2, 29.1] | 51.3 [54.7, 47.8] |
| n | 285 | 341 | 535 | 1,161 |
| MYBPC3-c.772G<A [95% CI] | 40.8 [53.5, 31.1] | 44.3 [50, 39.5] | 52.2 [58.5, 47.8] | 44.2 [50, 37.8] |
| n | 404 | 591 | 818 | 1,813 |
| Absolute Δ SRX (%) [95% CI] | −7.2 [6.4, −18.2] | −19.2 [-9, −38.4] | 16 [24.7, 7.2] | −7.1 [-0.3, −14.7] |
Measured values for the percentage SRX are given in bold and 95% CI in square brackets. The absolute difference in SRX as a result of PKA treatment relative to untreated myofibrils is given in the bottom row. The number of events (n) are shown in italics for each area of the thick filament and include nonspecific ATP binding events.